Skip to main content

Atossa Therapeutics, Inc.

ATOS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001488039

No open-market purchases or sales by Atossa Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $2.60M in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Atossa Therapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024All holders in Q1 2024

13F holders of ATOS: Q1 2024 compared with Q2 2024
MeasureQ1 2024Q2 2024Change
Holders6777+10
Shares19.2M26.2M+6.98M (+36.3%)
Value$34.6M$31.2M−$3.48M (−10.1%)

New holders (27)

Institutions that held Atossa Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to ATOS in Q2 2024
InstitutionSharesValue% of portfolio
Nuveen Asset Management, LLC170,733$203.2K0.00%
Rhumbline Advisers135,118$160.8K0.00%
New York State Common Retirement Fund87,800$104.5K0.00%
Corebridge Financial, Inc.68,049$81.7K0.00%
Invesco Ltd.57,901$68.9K0.00%
Voya Investment Management LLC46,349$55.2K0.00%
Barclays PLC44,035$52.4K0.00%
MetLife Investment Management33,405$39.8K0.00%
XTX Topco Ltd24,665$29.4K0.00%
Alliancebernstein L.P.17,380$20.7K0.00%
NorthRock Partners, LLC16,750$19.9K0.00%
Victory Capital Management Inc16,200$19.3K0.00%
Koss-Olinger Consulting, LLC15,000$18.0K0.00%
GWM Advisors LLC15,000$17.9K0.00%
Ground Swell Capital, LLC14,466$17.2K0.02%
Principal Financial Group Inc13,207$15.7K0.00%
Ameritas Investment Partners, Inc.12,392$14.7K0.00%
Alpine Global Management, LLC12,168$14.5K0.00%
Legal & General Group Plc11,829$14.1K0.00%
SG Americas Securities, LLC11,812$14.0K0.00%
Janney Montgomery Scott LLC11,500$14.0K0.00%
Evanson Asset Management, LLC10,000$11.9K0.00%
California State Teachers Retirement System9,165$10.9K0.00%
Amalgamated Bank4,376$5.00K0.00%
Planning Capital Management Corp1,000$1.19K0.00%
Unique Wealth Strategies, LLC166$2990.00%
Price T Rowe Associates Inc40,770$00.00%

Sold out (17)

Institutions that held Atossa Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.